Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

European Journal of Cancer

Volumn 50, Issue 9, 2014, Pages 1602-1609

  Angelergues, Antoine ^a   Maillet, Denis ^b   Fléchon, Aude ^b   Ozgüroglu, Mustafa ^c   Mercier, Florence ^d   Guillot, Aline ^e   Le Moulec, Sylvestre ^f   Gravis, Gwenaelle ^g   Beuzeboc, Philippe ^h   Massard, Christophe ⁱ   Fizazi, Karim ⁱ   De La Motte Rouge, Thibault ^j   Delanoy, Nicolas ^a   Elaidi, Reza Thierry ^a   Oudard, Stéphane ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CENTRE LÉON BÉRARD   (France)

^c ISTANBUL UNIVERSITY   (Turkey)

^d STAT PROCESS   (France)

^e Institut de Cancerologie de la Loire   (France)

^f University of Paris Descartes   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h INSTITUT CURIE   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

Cabazitaxel; Castration resistant prostate cancer; Chemotherapy; Cytotoxic agents; Prostate specific antigen; Survival rate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG DOSE REDUCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

CABAZITAXEL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY; CYTOTOXIC AGENTS; PROSTATE-SPECIFIC ANTIGEN; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME;

EID: 84901228369     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.03.015     Document Type: Article

References (28)

1. S. Bracarda, C. Logothetis, C.N. Sternberg, and S. Oudard Current and emerging treatment modalities for metastatic castration-resistant prostate cancer BJU Int 107 2011 13 20
2. A.C. Mita, L.J. Denis, E.K. Rowinsky, J.S. Debono, A.D. Goetz, and L. Ochoa et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res Off J Am Assoc Cancer Res 15 2 2009 723 730
3. P. Vrignaud, D. Sémiond, P. Lejeune, H. Bouchard, L. Calvet, and C. Combeau et al. Preclinical antitumor activity of cabazitaxel, a semi-synthetic taxane active in taxane-resistant tumors Clin Cancer Res 19 11 2013 2973 2983
4. J.S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J.-P. Machiels, and I. Kocak et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 9747 2010 1147 1154
5. T.A. Yap, C.J. Pezaro, and J.S. de Bono Cabazitaxel in metastatic castration-resistant prostate cancer Expert Rev Anticancer Ther 12 9 2012 1129 1136
6. Y. Loriot, and K. Fizazi Taxanes: still a major weapon in the armamentarium against prostate cancer Eur Urol 63 6 2013 983 985
7. K. Fizazi, R. Thuret, C. Theodore, D. Prapotnich, M. Di Palma, and B. Escudier et al. Early PSA rise subsequently followed by PSA decline is a common event in prostate cancer patients responders to chemotherapy Ann Oncol 15 Suppl. 3 2004 iii114 427P
8. P.J. Olbert, A. Hegele, P. Kraeuter, A. Heidenreich, R. Hofmann, and A.J. Schrader Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel Anticancer Drugs 17 8 2006 993 996
9. T. Nelius, T. Klatte, W. de Riese, and S. Filleur Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy Int Urol Nephrol 40 1 2008 97 104
10. R. Thuret, C. Massard, M. Gross-Goupil, B. Escudier, M. Di Palma, and A. Bossi et al. The postchemotherapy PSA surge syndrome Ann Oncol Off J Eur Soc Med Oncol ESMO 19 7 2008 1308 1311
11. A. Sella, C.N. Sternberg, I. Skoneczna, and S. Kovel Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer BJU Int 102 11 2008 1607 1609
12. T. Nelius, and S. Filleur PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy Prostate 69 16 2009 1802 1807
13. H.I. Scher, S. Halabi, I. Tannock, M. Morris, C.N. Sternberg, and M.A. Carducci et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol Off J Am Soc Clin Oncol 26 7 2008 1148 1159
14. A.J. Armstrong, E. Garrett-Mayer, Y.-C. Ou Yang, M.A. Carducci, I. Tannock, and R. de Wit et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol Off J Am Soc Clin Oncol 25 25 2007 3965 3970
15. I.F. Tannock, R. De Wit, W.R. Berry, J. Horti, A. Pluzanska, and K.N. Chi et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 2004 1502 1512
16. M.-L. Zhu, C.M. Horbinski, M. Garzotto, D.Z. Qian, T.M. Beer, and N. Kyprianou Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res 70 20 2010 7992 8002
17. M.S. Darshan, M.S. Loftus, M. Thadani-Mulero, B.P. Levy, D. Escuin, and X.K. Zhou et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Cancer Res 71 18 2011 6019 6029
18. M. Thadani-Mulero, D.M. Nanus, and P. Giannakakou Androgen receptor on the move: boarding the microtubule expressway to the nucleus Cancer Res 72 18 2012 4611 4615
19. L. Gan, S. Chen, Y. Wang, A. Watahiki, L. Bohrer, and Z. Sun et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer Cancer Res 69 21 2009 8386 8394
20. C. Mahler Is disease flare a problem? Cancer 72 12 Suppl. 1993 3799 3802
21. A.Y. Liu, L.D. True, L. LaTray, W.J. Ellis, R.L. Vessella, and P.H. Lange et al. Analysis and sorting of prostate cancer cell types by flow cytometry Prostate 40 3 1999 192 199
22. H.G. Van der Poel, G.O. Oosterhof, H.E. Schaafsma, F.M. Debruyne, and J.A. Schalken Intratumoral nuclear morphologic heterogeneity in prostate cancer Urology 49 4 1997 652 657
23. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat Rev Cancer 1 1 2001 34 45
24. S. Halabi, A.J. Armstrong, O. Sartor, J.S. de Bono, E.B. Kaplan, and E.J. Small Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy J Clin Oncol 30 Suppl. 2012 [abstr. 4515]
25. J.S. De Bono, H.I. Scher, R.B. Montgomery, C. Parker, M.C. Miller, and H. Tissing et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res Off J Am Assoc Cancer Res 14 19 2008 6302 6309
26. H.I. Scher, X. Jia, J.S. de Bono, M. Fleisher, K.J. Pienta, and D. Raghavan et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data Lancet Oncol 10 3 2009 233 239
27. S. Kwee, M.-A. Song, I. Cheng, L. Loo, and M. Tiirikainen Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer Clin Transl Sci 5 1 2012 65 70
28. D.C. Smith, M.R. Smith, C. Sweeney, A.A. Elfiky, C. Logothetis, and P.G. Corn et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol Off J Am Soc Clin Oncol 31 4 2013 412 419